InvestorsHub Logo
Followers 4
Posts 121
Boards Moderated 0
Alias Born 08/10/2005

Re: None

Wednesday, 04/13/2016 4:47:05 PM

Wednesday, April 13, 2016 4:47:05 PM

Post# of 3683
Translation not so good, take it for what it's worth. No guarantee on the translation accuracy.

Mizuho Securities. 4/13/2016

http://kabutan.jp/

U.S. Athersys shows efficacy against acute cerebral infarction in the Phase 2 study. Conservative stock spread originates from a new field of cell medicine.

Current point, there is no choice of other treatments for this serious life threatening disease. In that, this will change the way of thinking with more and more use, that can be expected.

Domestic health care costs are rising, tailwind in early treatment promotion of this disease is necessary to long-term care, such as cerebral infarction.

"BUY" rating and raised the target price to 1660 yen ($15.19 usd) to 1960 yen ($17.94).

"MK" Kabusagu News